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Protocol
AbstrACt
Introduction The aim of the QUIDS study is to develop 
a decision support tool for the management of women 
with symptoms and signs of preterm labour, based on 
a validated prognostic model using quantitative fetal 
fibronectin (qfFN) concentration, in combination with 
clinical risk factors.
Methods and analysis The study will evaluate the Rapid 
fFN 10Q System (Hologic, Marlborough, Massachusetts) 
which quantifies fFN in a vaginal swab. In part 1 of the 
study, we will develop and internally validate a prognostic 
model using an individual participant data (IPD) meta-
analysis of existing studies containing women with 
symptoms of preterm labour alongside fFN measurements 
and pregnancy outcome. An economic analysis will be 
undertaken to assess potential cost-effectiveness of the 
qfFN prognostic model. The primary endpoint will be the 
ability of the prognostic model to rule out spontaneous 
preterm birth within 7 days. Six eligible studies were 
identified by systematic review of the literature and five 
agreed to provide their IPD (n=5 studies, 1783 women and 
139 events of preterm delivery within 7 days of testing).
Ethics and dissemination The study is funded by 
the National Institute of Healthcare Research Health 
Technology Assessment (HTA 14/32/01). It has been 
approved by the West of Scotland Research Ethics 
Committee (16/WS/0068).
PrOsPErO registration number CRD42015027590.
Version Protocol version 2, date 1 November 2016.
IntrOduCtIOn 
The overall aim of the QUIDS study is to 
develop a decision support tool for the 
management of women with symptoms and 
signs of preterm labour, based on a validated 
prognostic model using quantitative fetal 
fibronectin (qfFN) testing. The study has 
been conceptually divided into two parts. 
In this, the protocol for QUIDS part 1, we 
detail the protocol for development and 
internal validation of the prognostic model. 
In the protocol for QUIDS part 2, we detail 
the protocol for the prospective cohort for 
external validation of the prognostic model 
and acceptability testing.1 
Preterm delivery (before 37 weeks) occurs in 
7.1% of pregnancies in the UK (>50 000 deliv-
eries per annum), with the majority the result 
of preterm labour.2 3 It remains the leading 
cause of neonatal morbidity and mortality, 
but timely interventions, such as antenatal 
steroids to promote lung maturity, magnesium 
sulfate for neuroprotection and delivery in a 
unit with appropriate neonatal care facilities, 
can improve neonatal outcome. Establishing 
a diagnosis of preterm labour is, however, 
difficult. Clinical signs are non-specific and 
false-positive diagnoses are common, with up 
to 80% of women with signs and symptoms 
of preterm labour remaining pregnant after 
7 days.4 5 Such diagnostic uncertainty means 
a large proportion of women with symptoms 
of preterm labour are treated unnecessarily 
to ensure benefits to the small proportion of 
babies that do actually deliver preterm.
strengths and limitations of this study
 ► Development of prognostic model and for validation 
in a separate prospective cohort study.
 ► Health economic analysis to determine cost-effec-
tiveness from National Health Service perspective.
 ► Not a randomised control trial to test effectiveness 
of the model on improved patient outcomes.
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It is understandable that both clinicians and pregnant 
women may prefer a ‘treat-all’ approach in women with 
symptoms of preterm labour, particularly in a setting 
remote from an appropriate neonatal unit; and in order 
to ensure steroid prophylaxis in case preterm delivery 
occurs. However, unnecessary interventions result in both 
a substantial economic burden to health services and in 
potential adverse maternal and neonatal events. Hospital 
admission and interhospital transfer have considerable 
cost implications and can be associated with enormous 
problems for women and their families due to physical 
separation and emotional stress.6 7 Neonatal cots become 
‘blocked’ in order to accept a preterm baby just in case 
delivery occurs; negatively impacting the efficiency of 
already stretched neonatal units and networks. This 
frequently has knock-on effects to other women and 
babies, who may need transfer to another unit due to 
lack of cot availability despite an empty, but ‘blocked’, 
cot. It also may increase the number of ex utero trans-
fers, which are associated with poorer outcomes than in 
utero transfers.8 If preterm labour has been wrongly diag-
nosed, and delivery does not occur, steroids may also have 
adverse long-term consequences for the baby, especially if 
multiple courses are given.9 Tocolytic therapy, even when 
appropriate, can have serious side effects for both mother 
and baby.10 Lastly, uncertainty of outcome may contribute 
to the high anxiety scores seen in women with threatened 
preterm labour and their partners.11
Diagnostic tests for preterm labour are available and 
used in many units in the UK. fFN (Hologic, Marlbor-
ough, Massachusetts, USA) is a biochemical marker 
of preterm labour that can be measured in samples of 
cervicovaginal secretions collected at a speculum exam-
ination. It has potential to help improve diagnosis of 
impending preterm delivery.12 Other biochemical tests 
available include Actim Partus (Medixbiochemica, 
Espoo, Finland), which measures phosphorylated insu-
lin-like growth factor binding protein-1, and PartoSure 
(Parsagen Diagnostics, Boston, Massachusetts, USA), 
which measures placental alpha microglobulin-1. An 
alternative approach (which can be combined with fFN) 
is to measure the cervical length using transvaginal ultra-
sound, as the longer the cervix is, the less likely a preterm 
delivery.12
As part of a National Institute of Healthcare Research 
Health Technology Assessment (NIHR HTA) report, 
Honest et al found that a qualitative fFN test (giving a 
positive or negative result based on a single threshold 
of 50 ng/mL) was potentially useful in the prediction 
of preterm delivery <34 weeks gestation, with its main 
benefit relating to its high negative predictive value, that 
is, its ability to rule out impending delivery.12 A more 
recent HTA-funded review found that qualitative fFN 
testing has moderate accuracy for predicting preterm 
birth with overall sensitivity and specificity estimates of 
76.7% and 82.7% for delivery within 7–10 days.13 These 
estimates suggest that qualitative testing on its own would 
not have the sensitivity to rule out preterm delivery 
adequately, although in systematic review of clinical trials, 
no increase in neonatal morbidity or mortality was seen in 
association with false-negative fFN results.13 The authors 
concluded that this observation is likely to relate to the 
multifactorial nature of assessment of the risk of preterm 
delivery, where, in practice, fFN is just one component of 
the clinical assessment on which management decisions 
are based.13
Both HTA reviews described above examined the perfor-
mance of a qualitative fFN test, which provided a positive 
or negative result on the basis of a single threshold of 
50 ng/mL. Recently, this test has been replaced in the UK 
with the Rapid fFN 10Q System, which provides a concen-
tration of fFN within 10 min, and thus may be a more 
useful predictor of preterm delivery (qfFN). We surveyed 
current practice in UK maternity units (response rate 66% 
(137/207); March–July 2014).14 135/137 units (98.5%) 
use some sort of diagnostic test of preterm labour. The 
most common test is fFN (84/137 units; 61.3%). fFN is 
now only available with a quantitative analyser in the UK, 
but there is no consensus as to which women to use the 
test in, or how to interpret the results. Developing and 
evaluating a decision support for qfFN is thus likely to 
improve decision-making, even if qfFN is already available 
in clinical practice. Evidence about the potential value of 
the new qfFN is required, along with guidance about how 
to interpret results. The QUIDS study will address this 
evidence gap.
MEthOds And AnAlysIs
Aims and methodologies
The aim of the QUIDS study is to develop a decision 
support tool for the management of women with symp-
toms and signs of preterm labour, based on a validated 
prognostic model using qfFN testing.
The study protocol has been divided into two parts (see 
flow chart in figure 1). The protocols for parts 1 and 2 are 
reported in separate manuscripts.
Part 1: Development and internal validation of prognostic model 
(1) Individual participant data (IPD) meta-analysis to 
develop a prognostic model using qfFN and other risk 
(prognostic) factors and to evaluate the added value 
of qfFN towards this prognostic model performance. A 
prognostic model will be developed and internally vali-
dated15 16 based on a meta-analysis of IPD from existing 
prospective cohort studies where qfFN results and 
pregnancy outcome details are available. The primary 
outcome will be delivery within 7 days, although other 
endpoints will be included if recommended by focus 
groups. 
(2)Economic analysis: To provide an economic ratio-
nale for the prognostic model and analyse its cost-ef-
fectiveness from the perspective of the National Health 
Service (NHS) to provide an economic rationale for the 
prognostic model and the risk factors included in it.
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Part 2: Validation and refinement of prognostic model
Part 2 involves a prospective cohort study and accept-
ability testing, with external validation (and, if necessary, 
refinement) of the prognostic model, and update of 
health economic model.1
Endpoints
The primary endpoint is spontaneous preterm delivery 
within 7 days of qfFN test, in women tested at less than 
36 weeks gestation. This is both an important endpoint 
for women and caregivers (determined in QUIDS Qual-
itative study—a preceding qualitative study to identify 
the decisional needs of women, their partners and clini-
cians; online supplementary material) as well as a clin-
ically important endpoint. Antenatal steroids (which 
significantly reduce morbidity and mortality in preterm 
babies17) are most effective if delivery occurs within 7 days 
of administration. As repeated doses of antenatal steroids 
may be harmful, it is crucial to ensure steroids are timed 
correctly.
A secondary endpoint suggested by the preceding 
QUIDS Qualitative study consultation (online supple-
mentary material) was delivery within 48 hours of qfFN 
test. This analysis will be performed if feasible to do so 
within the constraints of the data available for model 
development.
health technologies being assessed
The study will evaluate the Rapid fFN 10Q System 
(Hologic), which provides a concentration of fFN (ng/
Figure 1 Flow chart illustrating the design of QUIDS study and conceptual division into part 1 and part 2.1 qfFN, quantitative 
fetal fibronectin.
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mL or invalid) in a vaginal swab sample. Further details 
about the system and recommended sampling technique 
are provided in the QUIDS Protocol part 2.1
target population
The target population is pregnant women attending 
hospital with signs and symptoms of preterm labour.
how patients are involved in this study
Patient representatives were consulted during the 
protocol development and have been invited to join the 
project management group (PMG) and the trial steering 
committee (TSC). Prior to commencing QUIDS, we 
performed a qualitative study to determine the decisional 
needs of pregnant women with signs and symptoms of 
preterm labour, their partners and their caregivers. This 
is described in the separate protocol ‘QUIDS Qualitative’ 
(online supplementary material). The end product of 
QUIDS will be a decision support aid to help clinicians, 
women and their partners decide on management of 
threatened preterm labour, based on the results of the 
qfFN. In QUIDS Qualitative women and clinicians indi-
cated that they would prefer this to be on web-based or 
mobile app-based format, presenting the risk of preterm 
birth within 7 days of testing.
development of prognostic model
IPD meta-analysis
The proposed IPD meta-analysis was registered on Inter-
national Prospective Register of Systematic Reviews 
(CRD42015027590). Our IPD meta-analytical approach 
will follow existing guidelines, and our output will comply 
with TRIPOD (Transparent Reporting of a multivariable 
prediction model for Individual Prognosis or Diagnosis) 
statement.18
Inclusion criteria
We prespecified inclusion of prospective cohort studies 
or randomised controlled trials of women with signs and 
symptom of preterm labour (as defined by investigators) 
that include qfFN results determined by Rapid fFN 10Q 
System and pregnancy outcome data; and the principal 
investigator (PI) of which has agreed to collaborate and 
provide data.
Exclusion criteria
We will exclude studies where fFN concentration was 
measured by ELISA and studies where IPD is not available 
for meta-analysis.
Search strategy
When applying for funding for this study (April 2014), 
we performed a literature search for completed and 
ongoing cohort studies of qfFN using search terms for 
quantitative fetal/foetal fibronectin and preterm birth, 
including databases (MEDLINE, EMBASE, Cochrane 
Database of Systematic Reviews, Database of Abstracts 
of Reviews of Effects and HTA Database) and clinical 
trial registries (Cochrane Central Register of Controlled 
Trials,  ClinicalTrials. gov), general search engines (such 
as Google: https://www. google. co. uk) and systematic 
reviews. We also consulted preterm birth researchers and 
networks Royal College of Obstetricains and Gynaecolo-
gists Clinical Study Groups (RCOG CSG) British Maternal 
Fetal Medicine Society (BMFMS), Preterm Brith Interna-
tional Collaborative (PREBIC) and the manufacturers of 
qfFN, (Hologic) to help ensure capture of all relevant 
studies.
Study manuscripts and/or protocols were screened by 
two researchers. We identified a total of 10 studies of qfFN 
that were potentially eligible. Four early datasets (in three 
manuscripts) used ELISA to determine the concentration 
of fFN and were excluded as the different method of anal-
ysis and earlier period of study would increase heteroge-
neity.5 19 20 Therefore, six studies fulfilled the eligibility 
criteria (see table 1).
Establishment of the qfFN IPD collaboration
We contacted the PIs of the six eligible studies of qfFN 
and invited them to participate (see table 1). Five of these 
agreed to provide their IPD as evidenced by their involve-
ment as coapplicants on the funding application and/or 
coauthorship of this protocol (BM, van Baaren, AK, AS, 
ALD). The PI of the sixth study (Elovitz) indicated IPD 
may be available after publication of her study.
The five included studies (table 1) are European 
studies of women with symptoms of preterm labour, 
comprising 1783 women and 139 events of preterm 
delivery within 7 days of testing. They are from consul-
tant-led maternity units in the UK (three studies) and 
Europe (two studies). All women in the included trials 
provided informed consent for participation in clin-
ical trials, and for their IPD to be used in subsequent 
analyses.
Study quality assessment and data collection
IPD will be stored in a bespoke database on a secure 
server at the University of Edinburgh. PIs will be asked 
to provide de-identified data, and consider all recorded 
variables (even if not reported publications). We will 
assess study quality according to Quality assessment of 
diagnostic accuracy studies (QUADAS-2),21 Quality in 
Prognostic Studies (QUIPS)22 and Checklist   for critical 
Appraisal and data extraction for systematic Reviews of 
prediction Modelling Studies (CHARMS)23 guidelines.
Sample size considerations
The size of the IPD meta-analysis is limited by the 
number of studies with data available (table 1). In 
model development the number of covariates that can 
be considered is limited by the number of events, with 
guidance suggesting at least 10 events required for each 
covariate.24 25 In our IPD meta-analysis data, we have 139 
events (preterm labour within 7 days of testing) and 
therefore deemed that it was sensible to evaluate qfFN 
and up to 13 other factors (covariates) for potential 
inclusion in our model.
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Data items
The following factors which are thought to influence 
risk of spontaneous preterm birth will be requested and 
considered for inclusion as covariates in the prognostic 
model: qfFN concentration, previous spontaneous 
preterm labour, gestation at fFN test, age, ethnicity, 
body mass index, smoking, deprivation index, number 
of uterine contractions in set time period, cervical dila-
tation, vaginal bleeding, previous cervical treatment 
for cervical intraepithelial neoplasia, cervical length 
(measured by transvaginal cervical length), singleton/
multiple pregnancy, tocolysis and fetal sex. Up to 13 of 
these will be prespecified for inclusion, based on avail-
able data (we will only use variables which are available 
in each study), and ranking for likely clinical relevance 
as agreed by consensus of the project management 
team.
Data cleaning
Prior to analysis data will be checked for outliers and 
missing data will be identified. Descriptive statistics will be 
performed to summarise data. Problems identified will be 
discussed with the PI of the original study, and amended 
as indicated by consensus discussion.
Data analysis and prognostic model development
Multivariable logistic regression modelling will be the 
primary method of analysis. The primary endpoint for the 
prognostic model will be delivery within 7 days. Another 
endpoint found to be important in focus group consul-
tations performed in QUIDS Qualitative (online supple-
mentary material) included delivery within 48 hours, and 
we will use this as a secondary endpoint if feasible (ie, if 
sufficient number of cases with delivery within 48 hours). 
We will develop an initial model with qfFN concentration, 
and then consider a model with other predefined clinical 
predictor variables (see the Data items section).
Tocolysis (which may delay onset of labour, although 
likely not beyond 48 hours) will be included as a categor-
ical variable (administered/not administered). We will 
explore treatment effect by sensitivity analysis with and 
without the assumption that tocolysis could delay delivery 
within 48 hours by a maximum OR of 5.39, 95% CI 2.14 to 
12.34, based on data in Haas et al.26
As the outcome is binary, a logistic regression model-
ling framework will be used to develop the model. A 
multilevel structure will be used to account for clustering 
of patients within studies, and heterogeneity of the effects 
of included factors (hereafter called ‘predictors’) will be 
Table 1 Details of studies contributing data to IPD meta-analysis
PI Setting N Events Dates Inclusion Primary outcome
Studies with data available
  EQUIPP30 31 Professor AS 5 UK 
centres
452 14 2010–2012 22–35 weeks with 
symptoms of preterm 
labour
Delivery <34 weeks 
gestation
  EUFIS*32 Professor BM 10 
European 
hospitals
452 48 2012–2014 24–34 weeks with 
preterm contractions 
and intact membranes
Delivery within 
7 days of test
  APOSTEL I*33 van Baaren 10 Dutch 
hospitals
528 70 2009–2012 24–34 weeks with 
preterm contractions 
and intact membranes
Days to delivery 
truncated at 7 days
  QFCAPS
  (unpublished)
Dr AK London 
teaching 
hospital
86 2 2012–2014 24–34 weeks with 
symptoms of preterm 
labour
Singletons only
Delivery within 
7 days of test
  UCLH/Whit
  (unpublished)
Dr ALD 2 UK 
centres
262 5 2009–2010 22–35 weeks with 
symptoms of preterm 
labour
Delivery within 
7 days of test
Total 5 studies 1783 139
Studies where data may be available in future
  STOP study
  (https://clinicaltrials.
gov/ct2/show/
NCT01868308)
Professor M 
Elovitz
USA 
teaching 
hospital
700 NK 2011–2015 22–34 weeks 
Symptomatic women 
with singleton 
pregnancy
Delivery before 
37 weeks
*Study unpublished at time of search in April 2014; manuscript now published.
APOSTEL 1, Alleviation of Pregnancy Outcome by Suspending of Tocolysis in Early Labour; EQUIPP, Evaluation of Fetal Fibronectin with a 
novel bedside Quantitative  Instrument for the Prediction of Preterm birth; EUFIS, European Fibronectin Study; IPD, individual participant 
data; NK, not known; PI, principal investigator; QFCAPS, Quantitative fetalfibronectin, Cervical length and ActimPartus for the prediction of 
Preterm birth in Symptomatic women; STOP, Screening to Obviate Preterm Birth; UCLH/WHIT, Univesity College London Hospital/Whittington 
Hospital Study. 
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accounted for using random effects, with between-study 
heterogeneity quantified using the estimated variance 
(τ2) and the I2 statistic. A separate intercept term per 
study will be included in the model, to account for the 
clustering and also gauge how predictions may require 
tailoring to different populations. Predictors with large 
heterogeneity in the prognostic effect across studies may 
be removed to ensure summary beta terms in the model 
are meaningful (accurate) for individual populations.16
In the primary analysis, we will use data from the first 
recorded attendance with signs and symptoms of preterm 
labour to determine the relationship between that indi-
vidual episode and outcome. Data from subsequent atten-
dances will be analysed subsequently, and may be included 
in an appropriate model. As a parsimonious model is 
sought, to reduce the factors included in the model that 
may otherwise delay its use, we will use backward stepwise 
selection based on an information criterion (eg, Akaike’s 
information criterion p<0.15) to identify a parsimonious set 
of factors to be included in the model; hereafter these are 
referred to as included ‘predictors’. Further, an approach 
of adding specialist tests, such as cervical length, only after 
considering simpler clinical assessment will be used, to 
maximise the utility of the model by ensuring that extra 
tests with their additional costs are only be included if they 
add to the predictive power.
Linearity between continuous variables and outcome will 
be assessed using cubic spline plots and data will be trans-
formed where appropriate before inclusion in multivari-
able analysis (eg, using fractional polynomial methods). 
Missing data will be assessed to determine whether missing 
at random is appropriate, and if so, multiple imputation 
of observed participant characteristics will be used, with 
missing data imputed within each original study separately, 
before the meta-analysis. The results of these analyses will 
be compared with a complete case analysis.
Assessing apparent model performance
The apparent performance of the model will be assessed 
by its overall fit, and the observed discrimination and cali-
bration in the IPD used to develop the model. Overall, 
fit of the models will be expressed with Nagelkerke R2. 
The ability of the models to discriminate between women 
with and without spontaneous preterm birth will be 
determined by the area under the receiver operating 
characteristics (AUC) curve, also known as the C statistic. 
Agreement between predicted and observed proportions 
of women with spontaneous preterm birth will be visual-
ised using a calibration plot, and measured using calibra-
tion slope and calibration in the large.
Internal validation: assessing optimism in model performance
Apparent performance is likely to be optimistic, as it is 
examined in the same data used for model development. 
Therefore, internal validation will also be undertaken 
using a non-parametric bootstrap resampling technique 
in which each modelling step is repeated in each bootstrap 
sample, to obtain a new model in each bootstrap sample, 
and then its apparent performance (AUC and calibra-
tion slope) in the bootstrap sample is compared with 
its performance in the original dataset. The ‘optimism’ 
is the mean difference (across all bootstrap samples) 
between the apparent value in the bootstrap sample and 
the observed value in the original dataset. This optimism 
estimate is then subtracted from the original model’s 
apparent performance, to give an optimism-adjusted esti-
mate of each measure of performance for the original 
model (eg, R2, C statistic, calibration slope).
Production of final model from IPD meta-analysis via uniform 
shrinkage
The optimism-adjusted calibration slope will be used as 
a uniform shrinkage factor, to adjust the parameter esti-
mates (log ORs) of the original model. The beta coef-
ficients in the original model will be multiplied by the 
shrinkage factor, and the study intercept terms re-esti-
mated to ensure perfect overall calibration is maintained 
(across all studies and, ideally, in each study separately). 
This will thereby produce a final model containing the 
updated intercepts and the shrunken beta coefficients.27 
With multiple intercepts, a strategy (or strategies) will be 
developed among the study investigators for which inter-
cept should be chosen for use when externally validating 
the model in a new population (eg, choose intercept from 
study that most closely resembles the population of appli-
cation); each strategy will be evaluated and compared in 
the cohort study external validation phase.
Added value of qfFN
The added value of qfFN will be examined throughout 
the whole model process, in particular its improvement 
on discrimination, calibration and other meaningful 
factors (such as clinical decisions) using appropriate 
techniques (such as net reclassification improvement and 
decision analysis methods).
Subgroup analyses
Subgroup analysis will be performed for multiple preg-
nancy, women with a previous preterm labour, gestation 
and those with criteria that are suggested to indicate 
preterm labour (number of uterine contractions in a set 
time period and/or cervical change). This will allow us 
to do a subgroup analysis in which we assess whether the 
predictive capacity of qfFN is similar in all subgroups.
Health economic analysis
An early-stage decision-analytical model will be built 
using evidence from current literature and from the IPD 
meta-analysis to explore the potential cost-effectiveness of 
different prognostic models including qfFN.
A literature review will be undertaken to inform model 
design and identify additional model parameters with 
searches of MEDLINE, EMBASE, Cochrane Library 
and the Paediatric Economic Database Evaluation for 
economic analyses including the use of fFN testing in 
woman with threatened preterm labour. Any evidence on 
resource use (test administration, treatments for preterm 
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labour, hospital stay, hospital transfers), quality of life 
and diagnostic outcome data from the IPD meta-anal-
ysis will be synthesised with the wider evidence based on 
current practice for women attending hospital with signs 
and symptoms of preterm labour. The economic analysis 
will be undertaken from the perspective of the UK NHS 
adhering to good practice guidelines and the National 
Institute for Health and Care Excellence reference case.28 
A decision tree will be developed to model the clinical 
pathway. The model will be used to explore potential 
cost-effectiveness of the prognostic model at different 
thresholds on the receiver operator characteristic curve, 
providing an economic rationale for the chosen prog-
nostic model.
EthICs And dIssEMInAtIOn
trial management and oversight arrangements
Project management group
The trial will be coordinated by a PMG, consisting of the 
grant holders (chief investigator and coapplicants), the 
trial manager, representatives from the Study Office and 
the Centre for Healthcare Randomised Trials (CHaRT-the 
supporting Clinical Trials Unit), plus service user repre-
sentatives (from the patient advisory group). The PMG 
will meet approximately every 4 months by teleconfer-
ence or face to face.
TSC and data monitoring committee
A combined TSC and data monitoring committee (DMC) 
will oversee the conduct and progress of the study. The 
terms of reference of the committee will be developed 
separately. Members of the TSC/DMC will consist of 
experts and two patient representatives.
Good clinical practice
The study will be conducted in accordance with the princi-
ples of Good clinical practice. Local research and develop-
ment approval will be obtained prior to commencement 
of the study at each site.
dissemination
On completion of the study, the study data will be 
analysed and tabulated, and a clinical study report 
will be prepared. Results will be communicated to 
the academic community via the scientific literature, 
attendance at conferences and invited presentations. 
TRIPOD reporting guidelines will be adhered to.18 
Summaries of results will also be made available to inves-
tigators for dissemination within clinics. Social media 
will be used to signpost publications and conference 
presentations and highlight important findings. Twitter 
and Facebook will be used to disseminate findings to 
professional organisations, charities, stakeholders and 
the public. Communication to the general public will 
further be facilitated by our close links with charities 
such as Tommy’s.29
Peer review
The study was extensively peer reviewed as part of the 
process of gaining grant funding from the National Insti-
tute of Healthcare Research (NIHR) HTA (14/32/01).
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